1263430-76-7

Basic information

• Product Name: C₄₇H₄₈N₂O₂S
• Synonyms: C₄₇H₄₈N₂O₂S
• CAS NO: 1263430-76-7
• Molecular Weight: 704.976
• Mol File: 1263430-76-7.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: C₄₇H₄₈N₂O₂S(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₇H₄₈N₂O₂S(1263430-76-7)
• EPA Substance Registry System: C₄₇H₄₈N₂O₂S(1263430-76-7)

Safety Data

• Hazardous Substances Data: 1263430-76-7(Hazardous Substances Data)

Upstream product

• 80441-55-0 6-(S-tritylmercapto)hexanoic acid 
• 107-15-3 ethylenediamine 
• 14470-28-1 mono-4-methoxytrityl chloride 
• 109938-55-8 mono-m-methoxytrityl chloride 
• 924273-15-4 6-(S-tritylsulfanyl)-hexaneamine 
• 114729-69-0 N¹-((4-methoxyphenyl)diphenylmethyl)ethane-1,2-diamine 

Downstream Products

• 1263430-78-9 C₅₂H₅₈N₂O₃S 

Relevant articles and documents

BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS

The invention relates to a process for the preparation of a hydrogel prodrug, comprising the steps of (a) providing a reactive biodegradable hydrogel, wherein said hydrogel comprises backbone moieties which are linked together through crosslinker moieties, each crosslinker moiety being terminated by at least two hydrolytically degradable bonds, and wherein from a branching core 3 to 16 linear PEG-based polymeric chains extend and wherein one terminus of said polymeric chains is connected to the branching core and the other to a hyperbranched dendritic moiety; wherein each said hyperbranched dendritic moiety has at least 3 branchings and at least 4 reactive functional groups; (b) conjugating a prodrug linker to a biologically active moiety, resulting in a biologically active moiety-prodrug linker conjugate; and (c) reacting the biologically active moiety-prodrug linker conjugate from step (b) with the reactive functional groups of the hydrogel of step (a). The invention further relates to a hydrogel prodrug obtainable from the process.

CONJUGATES COMPRISING AN GLP-1/GLUCAGON/GIP TRIPLE RECEPTOR AGONIST, A LINKER AND HYALURONIC ACID

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon/GIP triple receptor agonist, a linker and a hyaluronic acid hydrogel bearing - L1 -L2 - L - Y - R20 groups, wherein Y represents an GLP-1/Glucagon/GIP triple receptor agonist moiety; and -L is a linker moiety - by formula (la), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon/GIP triple receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon/GIP triple receptor agonist.

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND

The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition